Canopy Rivers Inc. (TSX.V: RIV)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV).

Canopy Rivers Inc. (TSXV: RIV) is pleased to announce it has entered into an arrangement agreement through its wholly-owned subsidiary, Canopy Rivers Corporation, with TerrAscend Corp. (CSE: TER) pursuant to which TerrAscend will restructure its share capital by way of a plan of arrangement under the Business Corporations Act (Ontario).

Canopy Rivers Inc. (TSX.V: RIV) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

• Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
• CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
• Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
• James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
• LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
• PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
• Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
• Solo Growth (TSXV:ALZ) is a premiere retail cannabis distributor that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Canada’s largest private liquor retailer, Solo Liquor, who collectively have more than 50 years of regulated substance retail experience. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy as “Solo Growth Corp.”
• Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
• TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
• Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (TSX.V: RIV), closed the day's trading session at $5.55, up 4.52%, on 1,873,887 volume with 2,536 trades. The stock's 52-week low/high is $3.188/$11.82.

Recent News

• Canopy Rivers Announces Proposed Restructuring of Investment in TerrAscend
• NetworkNewsBreaks – Canopy Rivers Inc. (TSXV: RIV) Quickly Progresses Into a Global Strategic Growth Platform
• 420 with CNW – Michigan Legislators Set to Approve Medical Cannabis Home Delivery

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) is pleased to announce the closing of the previously announced acquisition of HemPoland. The transaction has received approval from the Toronto Stock Exchange and cements the Company's commitment to building shareholder value through international expansion. Also today, CannabisNewsWire released a report highlighting the company, which examines the recent news that the Department of Revenue Administration in New Hampshire has revised its estimates of cannabis revenue upwards to $58 million annually if the products are taxed at 15%. These estimates come at a time when a committee is discussing a proposals to legalize recreational marijuana next year.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $5.0779, off by 3.28%, on 614,322 volume with 1,455 trades. The average volume for the last 3 months is 913,155 and the stock's 52-week low/high is $3.50/$10.24.

Recent News

• The Green Organic Dutchman Closes Acquisition of Hempoland, Providing Immediate Accretive Revenue and International Sales
• 420 with CNW – New Hampshire Raises Its Marijuana Revenue Projections
• The Green Organic Dutchman Closes Acquisition of Hempoland, Providing Immediate Accretive Revenue and International Sales

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE).

Global Payout Inc. (OTCPink:GOHE) (“Global”) and its wholly owned subsidiary MTrac Tech Corp. (“MTrac” or the “Company”) are pleased to announce that the new Pin Debit system has been deployed in one of the earliest merchants to sign on with MTrac, and the Company is pleased to report that the new system is live and has significantly increased the number of transactions processed through the MTrac Platform in recent days.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

Global Payout, Inc. (GOHE), closed the day's trading session at $0.0099, up 6.45%, on 2,837,102 volume with 79 trades. The average volume for the last 3 months is 5,283,629 and the stock's 52-week low/high is $0.0086/$0.159.

Recent News

• New MTrac Platform Increases Processing Volume Significantly Over Previous System
• MTrac Executes Exclusive Management & Development Agreement With Blockchain Based Point Of Sale Company, Cultivate
• 420 with CNW – FBI Data Shows Increased Marijuana Arrests in 2017

Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures, Inc. (OTC: NUGS) wants to be an open book. The company has announced the completion of a full audit for its fiscal year ended March 31, 2018. This marks the close of the three-year audit required as a condition of becoming a fully reporting company with the U.S. Securities & Exchange Commission (SEC). Cannabis Strategic Ventures will utilize the audit results to file future reports and disclosures with the SEC and move the company to fully reporting status. The company will also use the fully reporting status to uplist to a higher OTC Markets tier (http://nnw.fm/i8Swy).

Cannabis Strategic Ventures, Inc. (NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $3.08, up 3.70%, on 56,293 volume with 124 trades. The average volume for the last 3 months is 102,352 and the stock's 52-week low/high is $0.0309/$7.13.

Recent News

• Cannabis Strategic Ventures, Inc. (NUGS) Aims to Clear Higher Hurdle in Reporting Standards
• Cannabis Strategic Ventures, Inc. (NUGS) Boasts Robust, Ever-Growing Portfolio as it Cultivates the World’s Cannabis Brand Leaders
• NetworkNewsBreaks – Cannabis Strategic Ventures, Inc. (NUGS) Adapts to Evolving Market with Brand Specific Strategy

GreenBox POS, LLC (GRBX)

The QualityStocks Daily Newsletter would like to spotlight GreenBox POS, LLC (GRBX).

Hardware and software technology company GreenBox POS, LLC (OTC: GRBX) continues to meet its strategic goals head-on with a well-stocked suite of flagship products, services and custom hardware. The company recently completed the transfer of all business and assets of its parent company onto GRBX books in a transition that Executive Vice President Ben Errez said was accomplished without disrupting normal operations.

GreenBox POS, LLC (GRBX) is a hardware and software technology company that builds customized payment solutions in different industries. The company is headquartered in San Diego, California, with offices in Seattle, Wash.; Las Vegas, Nevada; and Vancouver, British Columbia, Canada. GreenBox, which has been awarded five provisional patents for its blockchain-based technology, delivers a fully integrated, intuitive, easy-to-use, point of sale (POS) system for a variety of businesses across a multitude of different market sectors.

GreenBox develops all software in-house and with international subsidiaries, which allows the company to provide individualized electronics modifications in partnership with different vendors. Custom POS machines are available as an upgrade from existing solutions currently in use. First-time merchants can also take advantage of custom-built kiosk machines powered by blockchain technology, complete with e-wallet integration downloadable via Android or iOS apps, or via installed cash-loading kiosks.

GreenBox develops POS (point of sale) software and hardware solutions; DEL (delivery app, APIs to POS and PAY); PAY (payment app, providing financial APIs to all other components); and KIOSK (deposit, cash and E-wallet management). The following flagship products, services and custom hardware are currently available:

• QuickCard – the QuickCard kiosk handles all cash issues, both for cashless operations and for legacy cash; performs direct and immediate deposits from cash to blockchain and confirms bank account availability within minutes. Accepts cash, debit/credit cards, or ACH directly to most banks while settling funds instantly. All records are stored securely on blockchain. No faster deposit solution is available in the regular and non-traditional banking systems (unless depositing cash directly into a cash machine connected to a bank branch).
• POS Solutions – GreenBox software, developed in-house and with international subsidiaries, features operational compliance, financial audit prep, expense tracking, tax payments, register-specific features, and data fidelity controls (backup/restore, cloud security, privacy, etc.). GreenBox POS software is fully integrated with Del and Pay Systems and features front register mode and back-end admin mode, in addition to in-admin mode to manage employees, vendors, expenses, taxes and compliance. All records are stored on blockchain with data reliably secured and protected.
• LOOPZ – This delivery software solution offers service dispatcher back-end technology with manual and automatic modes. The software is uniquely designed to be effectively utilized for mobile delivery service operations with full autonomous dispatch capabilities. LOOPZ provides the following features: two mobile apps (driver and consumer) running on Android and IOS; direct reporting to point of sale inventory and use of pay for instant settlements; separate escrow setup for tips and merchant sale; all data and information is securely hosted on a blockchain platform.

The management team at GreenBox includes CEO Fredi Nisan, who comes from the POS and merchant services business sector. He recently completed a successful exit in the POS and ERP business, which he founded and managed through the exit. Joining Nisan is Ben Errez, executive vice president, who comes from the investment, consulting and big software and hardware industries. His previous executive roles include positions at Microsoft (including engineering management of Microsoft Office for complex scripts); IBM (with which he had an exit); and Intel. Errez has also consulted the world’s biggest private economy, World Trade Center, on payment systems, security, reliability and privacy of software and hardware development.

GreenBox POS, LLC (GRBX), closed the day's trading session at $0.5275, up 1.42%, on 4,300 volume with 5 trades. The average volume for the last 3 months is 47,958 and the stock's 52-week low/high is $0.017/$1.95.

Recent News

• GreenBox POS, LLC (GRBX) Delivering Cashless Solutions to Meet Evolving Needs of Diverse Market Sectors
• 420 with CNW – Malaysia Considers Legalizing Medical Marijuana
• GreenBox POS, LLC (GRBX) Centers on Blockchain-Secured Ledger Technology

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

Cobalt resource estimates in North America just got a boost, after First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) (ASX: FCC) released the results of its first NI 43-101 Mineral Resource Estimate for its 100 percent-owned Iron Creek Cobalt Project in Idaho. The junior explorer announced Inferred Mineral Resources of 29.6 million tons (26.9 million tonnes) grading 0.11 percent cobalt equivalent, under a base case scenario, and an alternative underground-only scenario indicating 4.9 million tons (4.4 million tonnes) grading 0.30 percent cobalt equivalent (http://nnw.fm/Af2zz).

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.2405, up 0.17%, on 52,898 volume with 25 trades. The average volume for the last 3 months is 207,732 and the stock's 52-week low/high is $0.1983/$1.3041.

Recent News

• First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Reports Promising Initial Mineral Resource Estimate at Iron Creek Cobalt Project in Idaho
• First Cobalt Intersects High Grade Mineralization at Iron Creek
• First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Notes Initial Resource Estimates at Iron Creek Project ‘Exceed Expectations’

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) a royalty company for the U.S. licensed medical cannabis industry announced, that due to Cultivation Technologies Inc.’s, (“CTI”) re-focused business strategy, FinCanna and CTI have agreed to a restructured agreement (“RA”). Under the RA, FinCanna is to receive approximately US$3.9 million as repayment of CTI’s outstanding secured loan and receive payments equivalent to 3.44% of the consolidated topline revenue of CTI in perpetuity. Also today, CannabisNewsWire released a report highlighting the company which examines the recent news that federal district court has ruled that a nursing home violated the anti-discriminatory act when it rescinded a job offer to a job seeker who declared that she consumes medical cannabis off-duty and tested positive for THC in a pre-employment drugs test. Medical cannabis is legal in Connecticut where the plaintiff lives and sought to be employed by the nursing home.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.20892, up 8.25%, on 65,020 volume with 23 trades. The average volume for the last 3 months is 41,167 and the stock's 52-week low/high is $0.10/$0.8736.

Recent News

• FinCanna to Receive ~$3.9M USD Cash and Retain 3.44% Royalty in Perpetuity from CTI Royalty Restructuring Agreement
• 420 with CNW – Connecticut Federal Court Rules in Favor of Employees Taking Medical Marijuana
• FinCanna Investment Refined Resin Technologies Inc. Receives US$9.6 Million Minimum Purchase Order

TMSR Holding Company (NASDAQ: TMSR)

The QualityStocks Daily Newsletter would like to spotlight TMSR Holding Company (TMSR).

TMSR Holding Company (NASDAQ: TMSR), together with its subsidiaries, offers a clean alternative to traditional waste disposal to companies producing industrial solid waste in China. To view the full article, visit: http://nnw.fm/R2OFx.

TMSR Holding Company (NASDAQ: TMSR), together with its subsidiaries, is a recognized leader in the research, development, production and sale of solid waste recycling systems and zero emissions process systems, for the industrial and mining sectors in the People’s Republic of China. The company operates through its wholly owned business divisions: Shengrong Environmental and Wuhan HOST Coating Materials.

TMSR’s Shengrong subsidiary designs, builds, sells and services customized solid waste recycling systems and equipment for some of the largest industries in China. The company provides customers full-service, tailor-made systems from conceptual design to planning, production, modernization, optimization, assembly, start-up, conversions, disassembly, maintenance and servicing of components to complete zero emissions solid waste recycling and process systems.

Utilizing what management believed to be the world’s most advanced technologies of physical magnetic industrial solid waste recovery, Shengrong can process a variety of industrial solid waste materials and is able to extract valuable metal byproducts from the waste without generating any chemical pollution. Shengrong’s patented equipment can process aluminum slag, copper mine tailings, iron mine tailings, red mud manganese tailings, and molybdenum tailings among many others. Unlike traditional chemical-based recovery methods, the company extracts resalable metals from the waste without generating any pollution. The residues are processed to manufacture high-quality construction materials, turning polluted solid waste into valuable industrial materials with zero discharge.

Industrial solid waste recycling and heavy metal removal are significant worldwide technical, financial and environmental issues. Through Shengrong, TMSR is addressing this profound unmet market need by delivering end users a clean alternative to traditional waste disposal. The company intends to leverage these serious unmet needs, expand its patented industrial waste recycling systems to broad international markets, and provide global industrial and mining businesses cost-effective, patented green technology platforms that create new-found revenue streams for end users.

Through Shengrong, TMSR owns two U.S. patents and five patents granted by the Peoples Republic of China, including four invention patents and two utility model patents. The company’s research and development efforts have achieved technological advancements that allow end users to eliminate pollutant discharge as well as generate new revenue streams by selling valuable byproducts extracted from industrial waste.

TMSR subsidiary, Wuhan HOST Coating Materials, is the largest manufacturer of inorganic Zinc-rich resin and one-component epoxy Zinc-rich resin in China. Established in 2010, Wuhan HOST is a leader in the research and development, production and sale of Zinc-rich coating materials throughout the PRC and has a broad customer base that includes some of the foremost enterprises in major industries such as electricity, metallurgy, machinery, chemicals, bridge and shipping. TMSR completed the acquisition of 100% equity interest in Wuhan HOST Coating Materials on May 1, 2018.

Notably, TMSR first went public as JM Global Holding Company, a Special Purpose Acquisition Company (SPAC) formed to effect a merger, asset acquisition or other business combination that had exceptional growth potential. After reviewing over 50 potential targets and completing due diligence and third party analysis, JM Global identified China Sunlong Environmental Technology Inc. and its wholly owned subsidiaries as the acquisition target. Upon closing the business combination, the company was re-named TMSR Holding Company Ltd.

Demand for TMSR’s products is expected to grow significantly due to Chinese policies that encourage mining and manufacturing companies to adopt “green” technology. Approximately 3 billion tons of industrial solid waste were generated annually in China between 2011 through 2015.  Currently, 95% of industrial solid waste in China is stored in special facilities and sites; however, the cost of storage, disposal and incineration of industrial solid wastes is high. TMSR is focused on exploiting this unmet need, providing end users in the solid waste recycling markets a clean alternative to traditional waste disposal, significantly reducing solid waste discharge into the environment and enabling end users to extract value from industrial waste materials.

TMSR Holding Company (TMSR), closed the day's trading session at $2.0842, off by 3.06%, on 2,212 volume with 6 trades. The average volume for the last 3 months is 6,883 and the stock's 52-week low/high is $1.84/$10.322.

Recent News

• NetworkNewsBreaks – TMSR Holding Company Ltd. (NASDAQ: TMSR) Supporting the Principles of Sustainability in China
• NetworkNewsBreaks – TMSR Holding Company Ltd. (NASDAQ: TMSR) Pays Tribute to Departing Board Members, Welcomes New Ones
• TMSR Holding Company Limited (NASDAQ: TMSR) is a Recognized Leader in China’s $16B Solid Waste Recycling Industry

Koios Beverage Corp. (CSE: KBEV) (OTC: KBEVF)

The QualityStocks Daily Newsletter would like to spotlight Koios Beverage Corp. (KBEVF).

The preliminary findings on clinical trials into the cognitive benefit of nootropic beverages made by Koios Beverage Corp. (CSE: KBEV) (OTC: KBEVF:US) (the "Company" or "Koios"), indicate positive brain results, the Company reported today.

Koios Beverage Corp. (CSE: KBEV) (OTC: KBEVF) develops and distributes nature-based products that boost brain function, enhance health, and improve productivity. Its core vision is to help a billion people worldwide live more productively through the development of nootropics, which are supplements that improve cognitive abilities.

The company’s flagship product, Koios, is a GMP-certified dietary supplement. Made from natural ingredients and backed by science, Koios is designed to improve focus, memory, mental drive, clarity and energy. The company produces Koios in the following formulations:

• Powder supplements containing nootropics as well as caffeine and lion’s mane and chaga mushrooms;
• Vegan-friendly capsules;
• Canned beverages containing nootropics along with MCT oil to burn fat and increase metabolism.

Not to be mistaken with prescription-only drugs which are at times used for similar effects, nootropics are over-the-counter dietary supplements; some of which, like Koios, contain ingredients that are currently used in the treatment of patients with Alzheimer’s disease. The global field of nootropics is growing rapidly and expected to reach USD $6,059.4 Mn by 2024 with a CAGR of 17.9 percent from 2016 to 2024.

According to media reports, there is believed to be significant and growing use of nootropics among high-achieving students and professionals. The UK’s leading Guardian newspaper found that nootropics are commonly used in Silicon Valley by computer industry professionals who want to “hack” their minds and maximize their productivity without any possible negative effects on the brain.

Koios was born out of the personal struggles of its founder and CEO, Chris Miller, who has ADHD. Miller found that the symptoms of his condition held him back when navigating the competitive modern workplace. Unhappy with the effects of the Adderall he was prescribed, Chris began a search for a natural remedy that would improve his attention and mental capacity.

Speaking of his struggles at this time, Miller says, “Coffee and energy drinks were no longer helping me. Eventually, I was drinking so much caffeine that I was beginning to notice negative and troubling health effects.” He adds, “I believed there had to be a better way. Better technology that the earth was providing that I could implement and not only boost my daily performance but take care of my brain and body long-term.” After years of experiments and with the help of leading scientists, he developed Koios, named after the Greek Titan who represented rational intelligence.

Koios contains the following ingredients, among others:

• Vitamin B12: Crucial for the function of the nervous system and the synthesis of DNA, B12 also helps in the creation of red blood cells.
• Vitamin B6: This vitamin is crucial for brain development among children and brain function in adults. B6 is also important in the production of key hormones: serotonin, which regulates mood, norepinephrine, which helps us handle stress, and dopamine.
• Huperzine A: Developed from the Chinese club moss plant, huperzine A is used on Alzheimer’s patients to boost their memories. It is also used to raise energy levels and alertness and is the subject of medical trials to test its efficacy when combined with other drugs.
• Bacopa: Also known as brahmi, bacopa is an Indian herb used in Ayurvedic medicine to improve concentration and memory. Modern science has recognized its effectiveness, and it is used to treat symptoms caused by Alzheimer’s disease, ADHD and anxiety.
• Ciwujia: Sports scientists have been interested in this herb since they heard of how mountain climbers in Tibet use it to boost their performance at high altitudes. Peer-reviewed research has shown that Ciwujia has clear positive effects on endurance.

A full breakdown of Koios’ active ingredients is available on the company website.

Additionally, safety is paramount for Koios, with all its products developed in a high-grade nutraceutical laboratory which is GMP-certified and in compliance with FDA guidelines. Koios only uses high-quality ingredients sourced from the best possible locations in order to deliver a product that is not only safe but also “one of the world’s greatest nootropic blends.”

The company’s products can be found online and in stores, both across the United States and internationally, via a continuously growing distribution network.

Koios CEO Chris Miller is supported by a team with strong credentials in medical supplement start-ups, corporate finance and sales, which includes CFO/Director Anthony Jackson, Director Scott Walters, Director Konstantine Lichtenwald and Vice President of Sales Gina Burrus.

With people seeking a mental edge and cognitive boost, Koios believes that there is an opening in the market for its nature-based, over-the-counter nootropics, especially when current prescription medicines have worrying side effects..

Koios Beverage Corp. (KBEVF), closed the day's trading session at $0.5099, up 1.98%, on 122,586 volume on 77 trades. The average volume for the last 3 months is 465,590 and the stock's 52-week low/high is $0.001/$0.8142.

Recent News

• Clinical Trial Shows Positive Brain Activity Linked to Koios Beverages
• Koios Expands Retail Distribution to Include Alfalfa's Market
• 420 with CNW – Malaysia Considers Legalizing Medical Marijuana

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, this morning announced that it has initiated patient dosing in a phase I/IIa study of its lead clinical candidate, Bria-IMT, in combination with pembrolizumab [KEYTRUDA; manufactured by Merck & Co., Inc. (NYSE: MRK)] or ipilimumab [YERVOY; manufactured by Bristol-Myers Squibb Company (NYSE: BMY)]. To view the full press release, visit: http://nnw.fm/En44N.

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.0938, even for the day. The average volume for the last 3 months is 14,975 and the stock's 52-week low/high is $0.068/$0.1387.

Recent News

• NetworkNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Initiates Patient Dosing in Combination Study of Bria-IMT
• BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Lead Candidate Shows Promising Anti-Tumor Activity in Proof of Concept Study
• NetworkNewsAudio Announces Audio Press Release (APR) on BriaCell Therapeutics Corp. Achieving Superior Responses in Breast Cancer Immunotherapy Trials

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint, Inc. (OTC:SING) – announces the recently launched Bitcoin wallet application has surpassed 12,000 installs and is continuing increased activity. Recently the company launched a national TV campaign featuring Kevin Harrington an original Shark on ABC’s hit show Shark Tank. Fox Business commercial spot - https://youtu.be/sIPk1VRiSmk. Also today, the company was highlighted in an article about distribution partner, American Premium Water (OTC: HIPH), based in Playa Vista, California, which recently launched its CBD beverage, LALPINA Hydro CBD (http://nnw.fm/Gprh1).

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

• A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
• A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
• A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
• Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
• Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
• Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.03024, off by 3.23%, on 2,379,897 volume with 189 trades. The average volume for the last 3 months is 4,104,025 and the stock's 52-week low/high is $0.0235/$0.133.

Recent News

• SinglePoints’ Bitcoin Wallet SingleCoin Surpasses 12,000 Downloads in Successful National Launch
• NetworkNewsBreaks – American Premium Water Corp. (HIPH) Brings First Hydro-nano CBD Beverage to Market
• NetworkNewsAudio Announces Audio Press Release (APR) on SinglePoint, Inc. Endorsements Add to Credibility of Crypto and Blockchain

CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTC.QB: CYDY), CytoDyn unveils its strategy to complete development of PCaTest, a novel gene-based prognostic test for prostate cancer developed by ProstaGene.  Following the completion of CytoDyn’s previously announced proposed acquisition of assets from ProstaGene, the Company intends to initiate a clinical study designed to further demonstrate the superiority of the PCaTest compared with current genetic tests in predicting outcomes of individuals with prostate cancer.

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.554, off by 1.07%, on 98,653 volume with 45 trades. The average volume for the last 3 months is 362,184 and the stock's 52-week low/high is $0.40/$0.836.

Recent News

• CytoDyn Announces Strategy to Complete Development of Novel ProstaGene Gene-based Prostate Cancer Prognostic Test
• CytoDyn Inc. (CYDY) to Acquire Biotech Developing Therapies to Stop Cancer from Spreading
• CytoDyn Inc. (CYDY) Scheduled to Present at The MicroCap Conference on October 1

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

MARIJUANA COMPANY OF AMERICA INC. (OTC: MCOA), an innovative hemp and cannabis corporation, is pleased to announce that the Company has appointed Ian Harvey as the Global Sales Director of its wholly-owned UK subsidiary hempSMART™, Ltd. in preparation for the Company’s January 2019 product launch in Europe. Also today, CannabisNewsWire released a report on the company detailing how MCOA is benefiting from the growing public acceptance of medical marijuana, which is having secondary effects on other industries, and is doing so in many ways, having invested in hemp, CBD products, rentable cultivation space and payment systems.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0263, off by 2.59%, on 4,389,734 volume with 314 trades. The average volume for the last 3 months is 7,694,147 and the stock's 52-week low/high is $0.0219/$0.0728.

Recent News

• Marijuana Company of America Appoints Ian Harvey as Global Sales Director of hempSMART™ in Preparation of 2019 Launch in Europe
• Public Acceptance Fuels Growth of CBD and Support Industries
• Harvest Underway at Marijuana Company Of America’s CBD Hemp Operation In Scio, Oregon

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today details its branding strategy for Hygee™, a medical device designed for the detection of sexually transmitted infections (STIs) in women. With plans to market Hygee™ on five continents, ETST is deploying a striking graphic identity that will speak directly to women. Also today, ETST’s welcoming of the DEA decision to reschedule CBD, anticipating that its pure hemp oil and new formulas will eventually be sold globally and that it will be a licensed distributor and will work closely with pharmacists and researchers to serve the cannabis market has been strengthened by the DEA’s recent decision on CBD (http://cnw.fm/03dUM). Additionally, the company has highlighted in a report by CannabisNewsWire explaining how a federal district court has ruled that a nursing home violated the anti-discriminatory act when it rescinded a job offer to a job seeker who declared that she consumes medical cannabis off-duty and tested positive for THC in a pre-employment drugs test. Medical cannabis is legal in Connecticut where the plaintiff lives and sought to be employed by the nursing home.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

• Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
• Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
• KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $1.7285, off by 3.97%, on 121,648 volume with 207 trades. The average volume for the last 3 months is 81,670 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

• Earth Science Tech, Inc. (ETST) Promotes Women’s Health with Strategically Branded Self-sampling Kit
• Earth Science Tech, Inc. (ETST) Sees DEA Decision to Reschedule CBD Opening Doors for Development of Treatments for Multiple Illnesses
• 420 with CNW – Connecticut Federal Court Rules in Favor of Employees Taking Medical Marijuana